Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | August 19, 2020 | News story | Research and Development | coronavirus, top 10
Potentially unsafe coronavirus treatments are in the headlines this week, as President Donald Trump reportedly wants to approve Phoenix Biotechnology’s oleandrin as a coronavirus treatment, despite a lack of evidence for its effectiveness, while at least 800 people have died around the world from COVID-19 misinformation in the first three months of 2020, according to researchers.
In vaccine news, a top Russian doctor has quit the Health Ministry’s ethics council due to the quick approval process for the country’s coronavirus vaccine, while the UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of their vaccine candidates.
1. Top Russian doctor quits over questionable ethics that rushed through coronavirus vaccine approval – Published on 14/08/20
Professor Alexander Chuchalin has quit the Russian Health Ministry’s ethics council due to the quick approval process for the country’s coronavirus vaccine.
2. Trump allegedly “enthusiastic” for oleandrin to be approved as a COVID-19 treatment – Published on 18/08/20
President Donald Trump reportedly wants to approve Phoenix Biotechnology’s oleandrin as a coronavirus treatment, despite a lack of evidence for its effectiveness.
3. Coronavirus fake news has led to hundreds of deaths, according to a new study – Published on 13/08/20
At least 800 people have died around the world from COVID-19 misinformation in the first three months of 2020, according to researchers.
4. Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals – Published on 14/08/20
The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of their vaccine candidates to protect against COVID-19 infection.
5. COVID-19 patients are experiencing long-term effects from the virus – Published on 13/08/20
Almost a third of doctors have treated patients for long-term symptoms caused by coronavirus, according to a new study.
Related Content
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s weekly COVID-19 news round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …
